Gut microbiota and short‐chain fatty acid alterations in cachectic cancer patients

Ubachs, Jorne; Ziemons, Janine; Soons, Zita; Aarnoutse, Romy; Dijk, David P J van; Penders, John; Helvoort, Ardy van; Smidt, Marjolein L.; Kruitwagen, Roy F.P.M.; Baade-Corpelijn, Lieke; Damink, Steven W. M. Olde; Rensen, Sander S.

doi:10.1002/jcsm.12804

Cited by 81 publications

(63 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Megamonas and Akkermansia showed significantly higher abundance in both the NC and BN groups. Ubachs et al (2021) demonstrated that Megamonas was decreased in the feces of cachectic cancer patients; in recurrent pancreatic tumor tissues, Akkermansia was decreased (Jeong et al, 2020). Additionally, Ren et al (2020) developed the nanoparticle NpRg3 to inhibit hepatocellular carcinoma development and metastasis by elevating the abundance of Verrucomicrobia.…”

Section: Discussionmentioning

confidence: 99%

Variations in the Gut Microbiota in Breast Cancer Occurrence and Bone Metastasis

Xie

Chen

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

Breast cancer is the most common cancer in women and the second most common cancer overall. Although advancements in the early diagnosis and therapy of breast cancer have occurred in recent years, the prognosis of breast cancer bone metastasis remains poor and this type of cancer is rarely cured. The gut microbiota is indispensable for internal homeostasis and regulates various biological processes. Understanding the gut microbiota profiles in normal controls (NCs), breast cancer patients with no metastasis (BNs), and breast cancer patients with bone metastasis (BMs) may shed light on the development of diagnostic and therapeutic targets for breast cancer and bone metastasis. We comprehensively analyzed the gut microbiota from NCs, BNs, and BMs and found that the community diversity decreased in the order of NCs, BNs, and BMs. Streptococcus, Campylobacter and Moraxellaceae showed higher abundances in BNs and BMs than in NCs. The lack of Megamonas and Akkermansia in the BM compared with those in the NC and BN groups was considered related to bone metastasis. Additionally, based on the distinct gut microbiota profiles, we predicted that lipid transportation and metabolism, as well as folate biosynthesis, participate in breast cancer occurrence and that steroid hormone biosynthesis influences bone metastasis. Our study demonstrated that variations in gut microbiota are associated with breast cancer occurrence and bone metastasis, providing attractive targets to develop therapeutic and diagnostic methods.

show abstract

Section: Discussionmentioning

confidence: 99%

Variations in the Gut Microbiota in Breast Cancer Occurrence and Bone Metastasis

Xie

Chen

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…[ 33 , 35 ]. Recently, two clinical studies detected the compositional differences in GM between two small cohorts of NSCLC patients with and without cancer cachexia [ 36 , 37 ]. Consistent with these studies, in our large cohort of NSCLC, we did not observe any differences in alpha diversity.…”

Section: Discussionmentioning

confidence: 99%

Cancer Cachexia among Patients with Advanced Non-Small-Cell Lung Cancer on Immunotherapy: An Observational Study with Exploratory Gut Microbiota Analysis

Hakozaki

Nolin-Lapalme

Kogawa

et al. 2022

Cancers

View full text Add to dashboard Cite

Cancer cachexia exerts a negative clinical influence on patients with advanced non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI). The prognostic impact of body weight change during ICI treatment remains unknown. The gut microbiota (GM) is a key contributor to the response to ICI therapy in cancer patients. However, the association between cancer cachexia and GM and their association with the response to ICIs remains unexplored. This study examined the association of cancer cachexia with GM composition and assessed the impact of GM on clinical outcomes in patients with NSCLC treated with ICIs. In this observational, prospective study, which included 113 Japanese patients with advanced NSCLC treated with ICIs, the prevalence of cachexia was 50.4% (57/113). The median progression-free survival (PFS) and overall survival (OS) were significantly shorter in the cachexia group than in the non-cachexia group (4.3 vs. 11.6 months (p = 0.003) and 12.0 months vs. not reached (p = 0.02), respectively). A multivariable analysis revealed that baseline cachexia was independently associated with a shorter PFS. Moreover, a gain in body weight from the baseline (reversible cachexia) was associated with a significantly longer PFS and OS compared to irreversible cachexia. Microbiome profiling with 16S rRNA analysis revealed that the cachexia group presented an overrepresentation of the commensal bacteria, Escherichia-Shigella and Hungatella, while the non-cachexia group had a preponderance of Anaerostipes, Blautia, and Eubacterium ventriosum. Anaerostipes and E. ventriosum were associated with longer PFS and OS. Moreover, a cachexia status correlated with the systemic inflammatory marker-derived-neutrophil-to-lymphocytes ratio (dNLR) and Lung Immune Prognostic Index (LIPI) indexes. Our study demonstrates that cachexia and longitudinal bodyweight change have a prognostic impact on patients with advanced NSCLC treated with ICI therapy. Moreover, our study demonstrates that bacteria associated with ICI resistance are also linked to cachexia. Targeted microbiota interventions may represent a new type of treatment to overcome cachexia in patients with NSCLC.

show abstract

“…A study has found that butyrate could inhibit proliferation of lung cancer by modulating p21 expression, and propionate could inhibit cell growth by inducing cell apoptosis and cell cycle arrest ( Kim et al., 2019 ). In addition, a recent study reported that SCFAs tended to be lower in cachectic cancer patients, which indicated that SCFAs may be crucial for clinical nutrition in cancer patients ( Ubachs et al., 2021 ). It is known that vancomycin mainly acts on gram-positive bacteria, including some butyrate-producing bacteria, which may lead to SCFA concentrations decreased ( Uribe-Herranz et al., 2020 ).…”

Section: Discussionmentioning

confidence: 99%

Analysis of Gut Microbiota Signature and Microbe-Disease Progression Associations in Locally Advanced Non-Small Cell Lung Cancer Patients Treated With Concurrent Chemoradiotherapy

Liu

Qiu

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

PurposeTo evaluate the association of gut microbiome signature and disease progression in locally advanced non-small cell lung cancer (LA-NSCLC) patients treated with concurrent chemoradiotherapy (CCRT) by fecal metagenome analysis.MethodsMetagenome-wide association studies on baseline fecal samples from 18 LA-NSCLC patients before CCRT and 13 controls from healthy first-degree relatives were performed. Among the 18 LA-NSCLC patients, six patients were defined as the long progression-free survival (long-PFS) group (PFS≥11 months) while another 12 were in the short-PFS group (PFS<11 months). Alpha diversity, taxonomic composition, and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional pathways were compared between groups.ResultsThe Firmicutes/Bacteroidetes value of long-PFS group was higher than those of short-PFS (p=0.073) and healthy individual groups (p=0.009). Meanwhile, long-PFS group had significantly higher diversities in Fungi, Archaea, and Viruses than short-PFS group. The KEGG pathways overrepresented in short-PFS group included fructose and mannose metabolism (p=0.028), streptomycin biosynthesis (p=0.028), acarbose and validamycin biosynthesis (p=0.013), ribosome biogenesis in eukaryotes (p=0.035), biosynthesis of vancomycin group antibiotics (p=0.004), apoptosis-fly (p=0.044), and tetracycline biosynthesis (p=0.044), while those overrepresented in long-PFS group included fatty acid biosynthesis (p=0.035), fatty acid metabolism (p=0.008), vancomycin resistance (p=0.008), longevity regulating pathway-worm (p=0.028), type II diabetes mellitus (p=0.004), and viral carcinogenesis (p=0.003). Further analysis of antibiotic resistome demonstrated that the short-PFS group had a trend with more antibiotic resistance genes than healthy control (p=0.070) and long-PFS groups (p=0.218). The vancomycin resistance sequences were significantly enriched in the long-PFS group compared to the short-PFS group (p=0.006).ConclusionsThe baseline gut microbiome composition and functionality might be associated with PFS in LA-NSCLC treated with CCRT. The outcome of CCRT might be modulated through bacterial metabolic pathways. The antibiotic resistance genes might play a role in disease progression and provide potential information on the relationship between the use of antibiotics and treatment efficacy of CCRT in LA-NSCLC.

show abstract

Gut microbiota and short‐chain fatty acid alterations in cachectic cancer patients

Cited by 81 publications

References 40 publications

Variations in the Gut Microbiota in Breast Cancer Occurrence and Bone Metastasis

Variations in the Gut Microbiota in Breast Cancer Occurrence and Bone Metastasis

Cancer Cachexia among Patients with Advanced Non-Small-Cell Lung Cancer on Immunotherapy: An Observational Study with Exploratory Gut Microbiota Analysis

Analysis of Gut Microbiota Signature and Microbe-Disease Progression Associations in Locally Advanced Non-Small Cell Lung Cancer Patients Treated With Concurrent Chemoradiotherapy

Contact Info

Product

Resources

About